Belzutifan: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), CHUIKYO (Japan) and G-BA (Germany), among others, recommended or restricted belzutifan, while DMC (Denmark) did not recommend it.
The record spans 3.5 years, opening at AWMSG (Wales) on 17 Mar 2023 and running to 21 Sep 2026.
CIPM (Spain) changed its position: not recommended on 28 Jan 2026, recommended by 20 May 2026, after a resubmission.
No assessment is on file from TLV (Sweden), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for belzutifan, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 18 of 18 records date from 2023 or later.
5 distinct indication wordings are recorded for belzutifan by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 18 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess belzutifan, on 17 Mar 2023; PHARMAC (New Zealand) did not open a file until 21 Sep 2026 — a wide spread of 3.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 18 dated records fall in 2025 alone.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed belzutifan to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), NICE (England) and ZIN (Netherlands).
5 of the 13 agencies here assessed belzutifan more than once, CIPM (Spain) most often at 2 entries — repeat review is the norm for this molecule rather than the exception.
belzutifan has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for belzutifan reads 6 recommended, 4 restricted, 2 no benefit and 2 not recommended, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| ZIN (Netherlands) | 26 Aug 2026 | Advies - alleen vergoeden na prijsdaling belzutifan (Welireg®) voor de behandeling van de ziekte van Von Hippel-Lindau | reimburse only after price negotiation (sluis) | source |
| AIFA (Italy) | 28 May 2026 | WELIREG in monoterapia è indicato nel trattamento di pazienti adulti con malattia di vonHippel-Lindau che necessitano di… | innovative status not granted · reimbursed class H | source |
| CIPM (Spain) | 20 May 2026 | Indicaciones terapéuticas autorizadas: Carcinoma de células renales (CCR): WELIREG en monoterapia está indicado para el … | financed by the SNS, on appeal · art. 92 a, c | source |
| AOTMIT (Poland) | 17 Dec 2025 | programu lekowego „Leczenie pacjentów z chorobą Von Hippel-Lindau (ICD-10: Q85.8) | recommended conditionally | source |
| DMC (Denmark) | 29 Oct 2025 | Voksne patienter med avanceret RCC, som er progredieret efter to eller flere behandlingslinjer, som inkluderede en PD-(L… | Ikke anbefalet | source |
13 further decisions for belzutifan, across 10 agencies, are not shown here. They include the most recent record on file, 21 Sep 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 13 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 18 decisions for belzutifan from 13 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.